Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia-Reference-Cited by-同舟云学术

Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia

Published:2022-07-07 Issue:1 Volume:140 Page:11-15
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Frey Noelle V.¹^ORCID

Affiliation:

1. Cell Therapy and Transplant, Division of Hematology Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA

Abstract

Abstract In October 2021, brexucabtagene autoleucel became the first anti-CD19 chimeric antigen receptor T-cell product to receive approval from the Food and Drug Administration to treat adults with relapsed and refractory B-cell acute lymphoblastic leukemia. The approval is based on results from the Zuma-3 trial and significantly widens treatment options for this patient population. In this article, we review outcomes from this study and its implications.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

https://ashpublications.org/blood/article-pdf/140/1/11/1905406/bloodbld2021014892c.pdf

Reference30 articles.

1. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia;Maude;N Engl J Med.,2018

2. Chimeric antigen receptor T cells for sustained remissions in leukemia;Maude;N Engl J Med.,2014

3. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma;Neelapu;N Engl J Med.,2017

4. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma;Schuster;N Engl J Med.,2019

5. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma;Wang;N Engl J Med.,2020

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions;Cancer;2024-08-02

2. SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024;Clinical Lymphoma Myeloma and Leukemia;2024-08

3. Genome editing approaches for universal chimeric antigen receptor T cells;EJC Paediatric Oncology;2024-06

4. New insights into immune cells in cancer immunotherapy: from epigenetic modification, metabolic modulation to cell communication;MedComm;2024-05-23

5. High-multiplex single-cell imaging analysis reveals tumor immune contexture associated with clinical outcomes after CAR T cell therapy;Molecular Therapy;2024-05